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Abstract: Background: Human milk oligosaccharide supplementation safely modulates fecal bifi-
dobacteria abundance and holds the potential to manage symptoms in irritable bowel syndrome (IBS).
Here, we aimed to determine the role of a 4:1 mix of 2′-O-fucosyllactose and lacto-N-neotetraose
(2′FL/LNnT) on the modulation of the gut microbiota composition and host mucosal response, as
well as the link between the bifidobacteria abundance and metabolite modulation, in IBS patients.
Methods: Biological samples were collected from IBS patients (n = 58) at baseline and week 4 post-
supplementation with placebo, 5 g or 10 g doses of 2′FL/LNnT. The gut microbiota composition,
metabolite profiles and expression of genes related to host mucosal response were determined.
Results: Moderate changes in fecal, but not mucosal, microbial composition (β-diversity) was ob-
served during the intervention with higher dissimilarity observed within individuals receiving
10g 2′FL/LNnT compared to placebo. Both fecal and mucosal Bifidobacterium spp. increased after
2′FL/LNnT intake, with increased proportions of Bifidobacterium adolescentis and Bifidobacterium
longum. Moreover, the intervention modulated the fecal and plasma metabolite profiles, but not
the urine metabolite profile or the host mucosal response. Changes in the metabolite profiles were
associated to changes in bifidobacteria abundance. Conclusion: Supplementation with 2′FL/LNnT
modulated the gut microbiota, fecal and plasma metabolite profiles, but not the host mucosal response
in IBS. Furthermore, the bifidogenic effect was associated with metabolite modulation. Overall, these
findings support the assertion that 2′FL/LNnT supplementation modulate the intestinal microenvi-
ronment of patients with IBS, potentially related to health.
Keywords: 2′-O-fucosyllactose; antibacterial response; gut microenvironment; human milk
oligosaccharides; irritable bowel syndrome; lacto-N-neotetraose; metabolomics; microbiota
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1. Introduction
Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder
driven by complex multifactorial mechanisms [1,2], typically characterized by recurrent
abdominal pain associated with altered bowel movements. IBS can be divided into clinical
subtypes based on the predominant bowel habits, i.e., diarrhea, constipation or mixed
bowel habits [3]. Patients with IBS may present alterations in the gut microbiota compo-
sition [4,5] and function [6,7], or activation of the mucosal immune system [8,9], in some
cases correlated to severity [4] or psychological symptoms [10]. Therefore, IBS may be
regarded as a gut–brain axis disorder, with the intestinal microenvironment as an important
player [11].
Host–microbiota interactions are central for maintaining gut health [12], and the gut
microbiota participates in the fermentation of undigested dietary components [13,14] and
modulation of neuro-immune interactions [15]. Growing evidence suggests that the gut
metabolome reflects the host–microbiota activity and also influences intestinal epithelial
cells and host immune responses [15,16], potentially regulating mucosal barrier functions.
Therefore, interventions aiming to modulate and improve an altered host-microbiota
crosstalk, and thereby potentially manage IBS symptoms, have emerged as an attractive
treatment strategy [17].
Human milk oligosaccharides (HMOs) are complex glycans naturally present in high
concentrations (5–25 g/L) in human breast milk [18]. Following ingestion, HMOs may be
minimally digested in the GI tract [19], absorbed intact into the circulation or excreted in
urine [20]. However, the majority of HMOs reach the large intestine undigested where they
act as a nutrient source for the microbial community [18]. HMOs promote the growth of
specific bacteria and have the potential to provide a health benefit [17]. Indeed, HMOs
have been shown to modulate microbiota and metabolite composition [21,22], promote
intestinal epithelial barrier protection [22,23] and immune responses [21,22,24] and thus,
may provide resilience against infections [25].
2′O-Fucosyllactose (2′FL) is one of the most abundant fucosylated HMOs, with a
mean concentration of 2.38 g/L in breast milk, whereas lacto-N-neotetraose (LNnT) is a
non-fucosylated HMO found in lower quantities (~0.28 g/L in breast milk) [26]. These
neutral HMOs have been extensively studied for their role in infant development [27].
However, less is known on their role in children [28] and adults [29]. Accordingly, the
well-established beneficial properties of HMOs in infants have prompted interest in ex-
ploring their potential to improve gut health in adults. A recent in vitro study using a
dynamic human gut simulator showed that fermentation of fecal samples, obtained from
a healthy adult donor, supplemented with either 2′FL, LNnT or a 4:1 mix of 2′FL and
LNnT (2′FL/LNnT) promoted the modulation of microbiota and metabolite profiles, and
specifically increased abundance of bifidobacteria and short-chain fatty acids (SCFAs) [22].
Furthermore, the resulting HMO-fermented products regulated claudins and secretion
of pro-inflammatory cytokines of CaCo2 cells and the gut-on-a-chip model system [22].
These in vitro findings suggest that HMOs have the capacity to regulate the intestinal mi-
croenvironment and thereby modulate barrier and immune functions of the gut in adults.
Furthermore, supplementation with 2′FL or LNnT, or a combination of both substrates, has
been shown to beneficially increase fecal bifidobacteria and shape microbiota composition
in healthy adults [29].
Although HMOs have been suggested as promising supplements for the management
of patients with microbiota–gut–brain axis disorders [30], studies of HMOs in patients with
IBS are still scarce. A large-scale open-label trial conducted in patients with IBS recently
demonstrated that 2′FL/LNnT supplementation improved GI symptoms and quality of
life [31]. In addition, our group recently reported in a placebo-controlled proof-of-concept
study that a mix of 2′FL/LNnT is well tolerated and beneficially impacts fecal bifidobacteria
abundance in IBS patients after a 4-week treatment period [32]. However, more detailed
studies exploring the effects of 2′FL/LNnT on the intestinal microenvironment in patients
with IBS are lacking. Here, we analyzed biological samples collected before and after the
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4-week daily supplementation with a 4:1 mix of 2′FL/LNnT [32] to test the hypothesis
that HMOs could modulate gut microbiota and metabolite profiles as well as the host
mucosal response in individuals with IBS. Furthermore, we determined the link between
HMO-induced bifidogenic effect and metabolite modulation throughout the intervention.
2. Material and Methods
2.1. Study Cohort
The study cohort has been previously described in detail [32] Briefly, female and
male (18–75 years) patients fulfilling the Rome IV criteria for IBS were recruited from the
specialized outpatient clinic for functional gastrointestinal (GI) disorders at Sahlgrenska
University Hospital (Gothenburg, Sweden) and local advertising between September 2016
and April 2018. All recruited patients presented moderate or severe IBS symptoms at
entry (IBS Symptom Severity Scale (IBS-SSS) ≥ 175), and we accepted IBS patients from all
subtypes based on the predominant bowel habits. All patients provided written informed
consent before the initiation of the study. Exclusion criteria are described in Supplementary
Material S1.
2.2. Study Design
The study was approved by the Regional Ethical Review Board in Gothenburg (Reg.
No. 548-16), as well as being registered at www.ClinicalTrials.gov (NCT02875847) (accessed
on 24 September 2018). The study was conducted between September 2016 and July 2018.
Glycom A/S (now DSM, Hørsholm, Denmark) was the sponsor. A phase II, parallel,
double-blind, randomized, placebo-controlled study was conducted in adult IBS patients
(n = 61 at randomization) as previously described [32]. Briefly, after a 2-week screening
period, patients were randomized and equally allocated to receive either placebo, 5 g
or 10 g doses of a 4:1 mix of 2′-O-fucosyllactose (2′FL) and lacto-N-neotetraose (LNnT)
(2′FL/LNnT) daily for 4 weeks. Patients were simultaneously stratified based on IBS
subtypes (IBS with predominant constipation (IBS-C), or diarrhea (IBS-D), or mixed bowel
habits (IBS-M)) within each intervention group. DSM provided 5 g and 10 g doses of
2′FL/LNnT as an active product. The 4:1 ratio of the 2′FL/LNnT mix selected aimed for an
approximate reflection of the proportions of 2′O-fucosyllactose and lacto-N-neotetraose
(4:1) within human breast milk based on previous reports [33,34]. The placebo control was
5 g of glucose (Dextropur, Dextro Energy GmbH and Co., Krefeld, Germany). Patients
were recommended to maintain their regular diet and medication throughout the study.
Following screening, the intervention period comprised two visits, at baseline and
week 4, and included collection of biological samples. Fecal samples were collected us-
ing sample collection and cooling kits at home, not earlier than 4 days prior to the visits
(baseline and week 4) and kept at −20 ◦C in freezers until handling. Additionally, mucosal
colonic biopsies, without bowel preparation, were taken during sigmoidoscopy and pre-
served in Allprotect Tissue Reagent (Qiagen, Hilden, Germany) for microbiota analysis and
RNA later solution (Thermo Scientific, Waltham, MA, USA) for gene expression analysis.
Whole blood was drawn from the antecubital vein by standard venipuncture techniques
and then processed to extract the plasma (heparin tube). The original study protocol did
not include urine sampling, but urine collection was approved after amendment of the
study protocol. As a result, urine was collected only for patients included in the study
after (19th September 2017). All samples were collected at Sahlgrenska University Hospital
(Gothenburg, Sweden) and stored at −80 ◦C after each visit until their use. Additionally, at
baseline, all patients completed validated questionnaires, the IBS symptom severity scale
(IBS-SSS) [35] and the Hospital Anxiety and Depression Scale (HADS) [36], to assess the
severity of IBS and psychological symptoms. Patients were re-assessed for these parameters
at the end of the intervention as previously reported [32]. See Supplementary Material S1:
Clinical questionnaires for more details.
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2.3. Gut Microbiota Analysis
Microbiota composition of fecal samples and mucosal colonic biopsies were analyzed
by 16S rDNA sequencing at the Clinical Microbiomics A/S (Copenhagen, Denmark).
Briefly, samples were mechanically disrupted using horizontal bead beating on a Vortex-
Genie 2 at 2700 rpm for 5 min and total bacterial DNA was isolated using NucleoSpin® 96
(Macherey-Nagel, GmbH and Co. KG, Düren, Germany). Then, a 16S rDNA Polymerase
Chain Reaction (PCR) amplified the V3–V4 region using universal bacterial 16S rDNA
primers [37] with Illumina adapters attached. A second PCR was run and included the
Nextera Index Kit V2 (Illumina). The sequencing was carried out on the Illumina MiSeq
sequencer using the MiSeq Reagent Kit V3 (Illumina). The analyses of the sequence data
were performed using USEARCH (version 10.0) [38], mothur (version 1.38) [39], and
internal scripts created by Clinical Microbiomics A/S. Reads with 97% sequence identity
were clustered as Operational Taxonomic Units (OTUs). The detailed protocol is described
in Supplementary Material S2.
2.4. Determination of Bifidobacterium spp. Levels
Assignment of the species level was attempted for Operational Taxonomic Units des-
ignated as Bifidobacterium (B.) spp. using the Nucleotide Basic Local Alignment Search
Tool (BlastN) software. B. adolescentis NC_008618; B. animalis subsp. lactis NC_012815;
B. bifidum NC_014638; B. catenulatum NZ_AP012325; B. dentium NZ_AP012326; B. galli-
narum NZ_JGYX01000004; B. longum NC_004307; and B. pseudocatenulatum NZ_AP012330
were selected as reference genomes.
2.5. Non-Targeted Metabolomic Analysis
Metabolite profiling was performed using fecal, plasma and urine samples by MS-
Omics (Copenhagen, Denmark). Fecal water, filtered urine and aqueous plasma were
obtained as described in Supplementary Material S2. The resulting samples were analyzed
by liquid chromatography-mass spectrometry (LC-MS) method using a UPLC system
(Vanquish, Thermo Fisher Scientific, Waltham, MA, USA) coupled with a high-resolution
quadrupole-orbitrap mass spectrometer (Q Exactive™ HF Hybrid Quadrupole-Orbitrap,
Thermo Fisher Scientific). LC method was based on an adapted version of a previously
established protocol [39]. Appropriate quality control (QC) samples were included through-
out the analysis and analyzed in tandem mass spectrometry mode to allow the identification
of compounds.
The raw data were processed on Compound Discovered software Version 3.0 (Thermo
Scientific, Thermo Fisher Scientific, Waltham, MA, USA) as described in Supplementary
Material S2. All compounds were processed and classified into different annotation levels
of decreasing confident identification as detailed in Supplementary Material S2. For further
statistical analysis, annotation levels 1, 2a and 2b were used and all values below the
limit of detection (LOD) were adjusted to the correspondent lowest value assigned to each
compound. Compounds identified in >50% of the samples below LOD, were excluded
from the analysis, together with compounds annotated as potential pharmaceutical drugs.
Furthermore, peaks corresponding to 2′FL and LNnT manually extracted from the raw
data were included in the corresponding metabolite profiles.
2.6. Gene Expression Analysis
Detection of 84 target genes related to the innate immune response against bacteria
(antibacterial genes) and five genes related to gut barrier function in mucosal colonic
biopsies was carried out using a quantitative PCR array (qPCR). Briefly, total RNA was
isolated from biopsies using the commercial kit of NucleoSpin® RNA Kit (Macherey-
NagelTM) according to the manufacturer’s protocol. From RNA, the cDNA was synthesized
using RT2 First Strand Kit (Qiagen).
The antibacterial genes were detected using RT2 Profiler™ PCR Array Human An-
tibacterial Response (Qiagen, Hilden, Germany) with RT2 SYBR Green qPCR Mastermix
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(Qiagen) in a QuantStudio 12K Real-Time PCR System (Applied Biosystems™, Life Tech-
nologies, Carlsbad, CA, USA). The list of all targeted genes can be found in Supplementary
Material S2: Table S1. The selected gut barrier function-related genes were amplified in
reactions containing QuantiTect SYBR Green PCR Master Mix (Qiagen, Hilden, Germany)
and the corresponding primers (see Supplementary Material S2: Table S2). The qPCR
was then performed using an Applied Biosystems® 7500 Real-Time PCR System (Thermo
Fischer Scientific, Waltham, MA, USA). All gene expression results were determined using
2−∆Ct method and normalized to the corresponding housekeeping genes. Similarly, the fold
change (week 4/baseline) was determined using the 2−∆∆Ct method. Further information
about both protocols can be found in Supplementary Material S2.
2.7. Statistical Analyses
Comparisons of demographic characteristics at baseline between the intervention
groups were performed based on normality of distribution using IBM SPSS Statistics for
Windows, Version 27.0 (Armonk, NY, USA; IBM Corp). Between-group comparisons were
performed based on the normality of distribution. A chi-square test was used for categorical
variables. ANOVA with Bonferroni’s correction was used for continuous variables.
Univariate analyses were applied to identify patterns in a single variable (e.g., α-
and β-diversity) of the intervention groups. A Kruskal–Wallis test followed by Dunn’s
correction was used for between-group comparisons while Mann–Witney U test assessed
pairwise comparisons between baseline and week 4. All analyses were carried out using
GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) and used p < 0.05 as cutoff for
statistical significance. Data were presented as median, median (interquartile range) or
median (10–90th), unless differently indicated.
For the gut microbiota analysis, the α-diversity was estimated to describe the variation
of microbiota composition within the samples at baseline and week 4. The number of
OTUs, related to the richness of the samples; and Shannon index, that includes both
richness and evenness (relative abundance) were performed by Clinical Microbiomics
A/S. The β-diversity (gut microbiota composition between samples) was estimated by
Bray-Curtis dissimilarity [40] in RStudio (R version 4.0.3, “Bunny-Wunnies Freak Out”)
and used rarefied relative sequence abundance. The potential effect of the 2′FL/LNnT
intervention on the metabolite and host mucosal response profiles were explored using
unsupervised analysis (principal component analysis (PCA)) in RStudio [41]. For this
purpose, a fold change (week 4/baseline) of each variable was calculated. Further, the
distance between centroids (score averages of each group) was estimated (Supplementary
Material S3: Multivariate analysis). Last, orthogonal partial least squares-discriminant
analysis (OPLS-DA) was performed to identify between-group differences on antibacterial
response modulation throughout the intervention using SIMCA® Software (version 16.0.2,
MKS Umetrics AB, Umeå, Sweden), similar to previously described [32].
3. Results
3.1. Demographics and Clinical Characteristics of the Study Cohort
In total, 58 IBS patients receiving either placebo, or 5 g or 10 g of 2′FL/LNnT daily
for 4 weeks, as previously reported [32], were included in this exploratory study. The
demographics and clinical characteristics of the patients at baseline are presented in Table 1.
Briefly, the cohort consisted of IBS patients of all subtypes, taking either placebo (n = 19),
5 g 2′FL/LNnT (n = 20) or 10 g 2′FL/LNnT (n = 19) for 4 weeks (Table 1). The distribution
of gender, age, body mass index, IBS severity and subtype, and psychological symptoms
were similar in the study groups (Table 1). All patients complied with the intervention
and followed the dietary advice [32]. Biological samples were obtained at baseline and
week 4, although urine samples were only provided by a limited number of patients. A
total of 116 fecal samples, 116 colonic mucosal biopsies, 115 plasma samples and 76 urine
samples were collected from the patients who completed the study. Samples were equally
distributed between intervention groups and visits.
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Sex (Female:Male) 14:5 11:9 14:5 0.35
Age, years † 45 (21−71) 42 (19−67) 47 (26−73) 0.65





IBS-C 5 5 4 0.93
IBS-D 8 9 8 0.96
IBS-M 6 6 7 0.95
IBS-SSS ¶
Mild 5 4 5 0.93
Moderate 7 11 5 0.30
Severe 7 5 9 0.57
HADS ¶
Anxiety:No anxiety 8:15 8:12 6:12 0.59
Depression:No depression 1:18 3:17 3:15 0.86
2′FL/LNnT, 4:1 HMO mix of 2′-O-fucosyllactose and lacto-N-neotetraose. IBS-C; irritable bowel syndrome (IBS)
with predominant constipation; IBS-D, IBS with predominant diarrhea; IBS-M, IBS with mixed bowel habits.
IBS-SSS, Irritable Bowel Syndrome-Symptom Severity Scale; HADS, Hospital Anxiety and Depression Scale.
† Mean and range (min–max). ¶ Number of patients. Differences between groups shown in bold (p < 0.05).
IBS-SSS scores: mild (<174); moderate (175–300); severe (>300). HADS questionnaire: anxiety ≥ 8 (clinically
relevant symptoms); no anxiety < 8; depression ≥ 8 (clinically relevant symptoms); no depression < 8.
3.2. Effect of 2′FL/LNnT on Fecal and Mucosal Microbiota Profiles
We first investigated the effect of 2′FL/LNnT on gut microbiota richness and diversity.
Species richness, determined as numbers of Operational Taxonomic Units (OTUs), of fecal
and mucosal samples were comparable in all intervention groups at baseline and after
the intervention (Figure 1A). Furthermore, Shannon index, a measurement of microbiota
diversity based on numbers of OTUs and relative abundance, was similar in both sample
types throughout the intervention (Figure 1B). Next, the fecal and mucosal β-diversity,
describing the change in microbiota diversity between two communities, were assessed.
Prior to the intervention, all groups presented with similar fecal and mucosal β-diversity
(Figure 1C). Further, the fecal and mucosal β-diversity at baseline was not distinct from
week 4 in any of the intervention groups (distance to group centroids and dispersion
between groups, p > 0.05) (Supplementary Material S4: Figure S1). However, in terms
of fecal microbiota, the change in microbiota composition within an individual overtime,
was higher in the group who received 10 g 2′FL/LNnT compared with placebo (p < 0.05),
whereas no differences between groups were detected with regards to mucosal microbiota
dissimilarity (Figure 1D).
3.3. Effect of 2′FL/LNnT on Microbial and Bifidobacterial Communities
The most abundant OTUs were identified as each bacterial taxon that is present in
more than 85% of the patient samples. The taxonomic analysis revealed that the 23 most
abundant OTUs detected constituted 60.1–65.0% of the median abundance in fecal samples
and 47.4–65.4% in mucosal biopsies. (Figure 2A). A high representation of the genera
Bacteroides, Blautia and Faecalibacterium as well as the Lachnospiraceae family in both
sample types were seen throughout the intervention (Figure 2A, Tables 2 and 3). The
relative abundance of some of these taxa changed after the intervention, as well as the
relative abundance of other abundant OTUs detected in fecal samples and mucosal biopsies
(Tables 2 and 3). For instance, both active groups demonstrated a decrease of mucosal
but not fecal Bacteroides at week 4 (p < 0.05). Moreover, fecal Faecalibacterium increased
in 5 g 2′FL/LNnT group (p < 0.01) while it remained stable in the mucosa at week 4.
Lastly, in the 10 g 2′FL/LNnT an increase of mucosal Blautia (p < 0.001) and a decrease
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of fecal Lachnospiraceae (p < 0.05) were recorded. Furthermore, supplementation with
5 g and 10 g 2′FL/LNnT, but not placebo, led to the increased relative abundance of
fecal and mucosal bifidobacteria at week 4 as compared to baseline (p < 0.05 and p < 0.01)
(Figure 2A,B,D, Tables 2 and 3). Within Bifidobacterium, a total of five species were identified,
and Bifidobacterium (B.) adolescentis and B. longum were present in more than 60% of the
samples (Supplementary Material S4: Tables S3 and S4). Supplementation with 5 g and
10 g of 2′FL/LNnT increased the relative abundance of fecal B. adolescentis (p < 0.05), and
mucosal B. adolescentis (p < 0.05) and B. longum (p < 0.01) at week 4 compared to baseline (p










Figure 1. Microbiota diversity measures from fecal and mucosal samples throughout the intervention
with 2′FL/LNnT or placebo in patients with irritable bowel syndrome (IBS). α-diversity, (A) Number
of OTUs (operational taxonomical units) and (B) Shannon index at baseline and after 4-week inter-
vention in placebo, 5 g 2′FL/LNnT and 10 g 2′FL/LNnT groups. β-diversity, (C) Between-patient
microbiota dissimilarity at baseline and (D) within-patient microbiota dissimilarity in fecal samples
and mucosal biopsies during intervention period in placebo, 5 g 2′FL/LNnT and 10 g 2′FL/LNnT
group. 2′FL/LNnT, 4:1 mix of 2′-O-fucosyllactose and lacto-N-neotetraose. (A,B) Data are shown as
median (10–90th percentile). (C,D) Dissimilarities were analyzed by Bray-Curtis dissimilarity index.
Dashed line at y = 0.5 indicates intermediate dissimilarity. Data are shown as median (interquartile
range). (A–D) Between-group comparisons calculated by Kruskal–Wallis test followed by Dunn’s
correction for multiple comparisons. * p < 0.05.
3.4. Effect of 2′FL/LNnT on the Metabolite Profile
Liquid chromatography-mass spectrometry allowed the detection of 384 metabolites
in fecal samples, 217 plasma metabolites and 528 urine metabolites. At baseline, the three
study groups did not differ with regards to fecal, plasma nor urine metabolite profiles
(Supplementary Material S4: Figure S2). However, significant changes in the fecal metabo-
lite profiles were detected, which were more marked in the intervention group which
received 10 g 2′FL/LNnT as compared to the groups receiving 5 g 2′FL/LNnT or placebo
(Figure 3A). Despite some overlaps, distinct fecal metabolite profiles of the intervention
groups were confirmed in separate PCAs (Figure 3D). 3-Hydroxy-3-methylglutaric acid
and N6-acetyl-L-lysine (compound nr 1733) were identified to have an important weight
in the separation between the group receiving 10 g 2′FL/LNnT and the group receiving
Nutrients 2021, 13, 3836 8 of 18
placebo, while N’-Hydroxy-2-(-1-naphthyl) ethanimidamide and N6-acetyl-L-lysine (com-
pound nr 1733) were major contributors to the separation between both active groups.
Furthermore, supplementation with 5 g of 2′FL/LNnT had the most pronounced effect
on the plasma metabolite profile as compared to placebo (p < 0.05) (Figure 3B,E), while
the 10 g dose showed a tendency in the same direction when compared to the placebo
group (p = 0.07) (Figure 3E). Asparagine and 7-methulguanine were identified among the
contributors to the separation between the groups receiving either 5 g 2′FL/LNnT and
placebo. However, no differences in the urine metabolite profiles were seen between the
intervention groups (Figure 3C,F). No peaks corresponding to 2′FL could be detected in
the fecal samples at any time point whereas 2′FL was detected above the detection limit
in a few plasma and urine samples at baseline. Furthermore, a significant increase was
observed at week 4 in the patients that received 5 g and 10 g HMO, while the placebo group
did not reveal such an increase (Table 4). Additionally, the peaks corresponding to LNnT
were not detected in either fecal, plasma or urine samples in any of the intervention groups.
Table 2. Relative abundance of the most abundant OTUs that were identified to be different in fecal samples between
baseline and week 4 in the groups receiving either placebo, 5 g 2′FL/LNnT and 10 g 2′FL/LNnT.
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B, Baseline; W4, Week 4. Data shown as median (min–max). Significant differences in bold; * p < 0.05, ** p < 0.01.
Table 3. Relative abundance of the most abundant OTUs that were identified to be different in mucosal biopsies between
baseline and week 4 in the groups receiving either placebo, 5 g 2′FL/LNnT and 10 g 2′FL/LNnT.
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Figure 2. Microbiota profile and Bifidobacterium spp. throughout the intervention period with
2′FL/LNnT or placebo. (A) Relative abundance of the 23 most abundant OTUs detected in fecal and
mucosal samples from placebo and 5 g 2′FL/LNnT and 10 g 2′FL/LNnT groups at baseline and
week 4. Relative abundance of (B) fecal and (D) mucosal bifidobacteria at baseline and week 4 in
placebo, 5 g 2′FL/LNnT and 10 g 2′FL/LNnT groups. (C) Relative abundance of fecal B. adolescentis
and B. longum at baseline and week 4. (E) Relative abundance of mucosal B. adolescentis and B. longum
at baseline and week 4. B., Bifidobacterium. (A) The median relative abundance is presented as
percentage (%). OTUs are identified at genus level in italics, except the order Clostridiales, and the
families Lachnospiraceae and Rumnicoccaceae. Percentages on top of each column indicate the
proportion that these OTUs occupy in the whole microbiota composition detected. (B–E) Data shown
as median (interquartile range), where each dot represents the relative abundance of each patient.
Baseline (empty symbol) and week 4 (filled symbol) in placebo (circle), 5 g 2′FL/LNnT (triangle) and
10 g 2′FL/LNnT (diamond) group. Between-group comparisons calculated by the Kruskal–Wallis
test followed by Dunn’s correction for multiple comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001.
3.5. Link between Effect on Bifidobacterium spp. Abundance and Metabolite Modulation
The modulation of the metabolite profiles was further investigated with regards
to the increased relative abundance of bifidobacteria in fecal samples. To this end, the
patients were classified into two groups based on the fold change of relative abundance
(week 4/baseline) of fecal bifidobacteria, using the upper quartile fold change of fecal
bifidobacteria in the placebo group as cutoff (Figure 4A). Of the 54 classified patients
(bifidobacteria relative abundance week 4/baseline > 0), 35% of IBS patients (placebo
n = 4, 5 g 2′FL/LNnT group n = 5, 10 g 2′FL/LNnT group n = 10) had a relative abundance
fold change of fecal bifidobacteria exceeding the mean fold change of the placebo group and
were, therefore, considered as having an effect on bifidobacteria abundance (Figure 4A).
Patients not meeting this criterion were considered to not have any bifidogenic effect
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following the intervention. The modulation of metabolite profiles was then compared
between these patient groups. At baseline, the fecal metabolite profiles did not differ
between the two groups of patients in any of the intervention groups (Supplementary
Material S4: Figure S2). However, in the 10 g 2′FL/LNnT group, but not in the 5 g group,
the fecal metabolite profile modulation tended to differ between patients displaying a
bifidogenic effect (Figure 4B). Asparagine, prolylleucine (compound nr 0163), N6-acetyl-L-
lysine (compound nr 1733), for example, were identified to have an important weight in
the separation between the 10 g 2′FL/LNnT subgroups (Figure 4B). Furthermore, in the 5 g
2′FL/LNnT group, but not in the 10 g group, the plasma metabolite profile modulation
differentiated depending on the bifidogenic effect, with for example tryptophan identified





Figure 3. Metabolite profiles during the intervention period with 2′FL/LNnT or placebo. Princi-
pal component analysis (PCA) plots based on the fold-change (week 4/baseline) of (A) 384 fecal
metabolites, (B) 217 plasma metabolites and (C) 528 urine metabolites in placebo (yellow circle), 5 g
2′FL/LNnT (teal triangle) and 10 g 2′FL/LNnT (blue diamond). Separate PCA plots presenting the
profile fold-change of (D) fecal metabolites, (E) plasma metabolites, and (F) urine metabolites of the
intervention groups in pairs: placebo and 5 g 2′FL/LNnT, placebo and 10 g 2′FL/LNnT and, 5 g
and 10 g 2′FL/LNnT. The p values in (D–F) indicate statistical significance between the score group
means (centroids).
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Table 4. Levels of 2′FL in plasma and urine samples.
Placebo 5 g 2′FL/LNnT 10 g 2′FL/LNnT



























Levels of 2′FL detected in plasma and urine samples at baseline and week 4 in each intervention group. Data
expressed as natural logarithm of the peak area and shown as mean (min–max). The limit of detection of 2′FL
was 6.6 peak area count in plasma samples and 6.7 peak area count in urine samples. Number of plasma samples:
placebo group, n = 19 baseline and n = 19 week 4; 5 g 2′FL/LNnT group: n = 20 baseline and n = 20 week 4; 10 g
2′FL/LNnT group: n = 18 baseline and n = 19 week 4. Number of urine samples: placebo group, n = 11 baseline
and n = 11 week 4; 5 g 2′FL/LNnT group: n = 12 baseline and n = 12 week 4; 10 g 2′FL/LNnT group: n = 11







Figure 4. The metabolite profile modulation in relation to the effect of the 2′FL/LNnT on bifidobacte-
ria (bifido effect). (A) Bifido effect based on the relative abundance fold change (week 4/baseline) of
Bifidobacterium spp. in fecal samples. The bifido effect was defined as a fold change of bifidobacteria
relative abundance during the intervention (week 4/baseline) greater than the upper quartile of the
relative abundance fold change in the placebo group (week 4/baseline > 3.70). The lack of increase in
bifido below the threshold was considered as “no effect”. (B) Principal component analysis (PCA)
based on the fecal metabolite fold change in patients who presented a bifido effect (dark color) and
no effect (light color) in the 5 g 2′FL/LNnT (left, teal triangles) and 10 g 2′FL/LNnT (right, blue
diamonds). 5 g 2′FL/LNnT group: n = 5 bifido effect and n = 15 no effect; 10 g 2′FL/LNnT: n = 10
bifido effect; n = 8 no effect. a prolylleucine (compound nr 0163), b N6-Acetyl-L-lysine (compound
nr 1733). (C) PCA based on the plasma metabolite fold change in patients who presented a bifido
effect and with no effect in the 5 g 2′FL/LNnT and 10 g 2′FL/LNnT. 5 g 2′FL/LNnT group: n = 5
bifido effect and n = 15 no effect; 10 g 2′FL/LNnT: n = 10 bifido effect; n = 8 no effect. PCA plots with
a clear separation between centroids show the loading of the most relevant metabolites involved in
the observed pattern. The p values in (B,C) indicate statistical significance between the score group
means (centroids).
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3.6. Effect of 2′FL/LNnT on the Host Mucosal Response Profile
The host mucosal response profile in colonic biopsies was determined, but no differ-
ences between the groups based on the antibacterial response gene expression profile (n = 80
expressed genes) before or throughout the intervention were identified (Figure 5A–C). The
OPLS-DA did not provide a good model, as the R2Y < 0.5 and Q2 < 0 values indicated
poor separation and predictability between the groups (Figure 5C). In addition, expression
of genes related to tryptophan metabolism, mast cell activation and intestinal epithelial
barrier function displayed comparable expression levels at baseline and after 4 weeks and






















Figure 5. Antibacterial response gene expression profile during the intervention period with
2′FL/LNnT or placebo. Biopsies obtained from IBS patients before and after 4-week interven-
tion were analyzed by polymerase chain reaction (PCR) array for 84 genes related to antibacterial
response. (A) A principal component analysis (PCA) based on 80 unique genes (4 genes excluded
due to expression below detection limit) at baseline in placebo (n = 19, yellow circle), 5 g 2′FL/LNnT
(n = 20, teal triangle) and 10 g 2′FL/LNnT (n = 19, blue diamond) groups. (B) PCA and (C) orthogonal
partial least squares-discriminant analysis (OPLS-DA) scatter plot of the antibacterial response gene
expression profile log2 fold change (week 4/baseline) during the intervention between placebo, 5 g
2′FL/LNnT and 10 g 2′FL/LNnT groups. The R2 value determines goodness of the fit and the Q2
value represents the predictive ability of the model. In biological models, R2Y ≥ 0.5 and Q2 ≥ 0.4 are
considered satisfactory.
4. Discussion
This exploratory study of patients with IBS revealed that supplementation with
2′FL/LNnT changed the overall fecal, but not mucosal, microbiota profile within pa-
tients after a 4-week intervention period. The 2′FL/LNnT supplementation also shaped
the relative abundance of specific bacterial taxa detected in fecal and mucosal samples,
specifically fecal and mucosal Bifidobacterium (B.) adolescentis and mucosal B. longum. While
2′FL/LNnT supplementation modulated the fecal and plasma metabolite profiles, only
2′FL was detected in plasma and urine after the intervention, and a distinct metabolite
modulation was linked to the effect of HMOs on bifidobacteria abundance throughout the
intervention. In contrast to microbiota and metabolite profiles, the host mucosal response
remained stable throughout the intervention period.
Little has been described about the effects of HMOs on gut microbiota composition in
adults and most studies are based on infant-based studies or pre-clinical models. While
fecal microbiota α-diversity was not altered in neonatal rats fed with 2′FL and controls [21],
the fecal microbial α-diversity of infants fed with formula supplemented with 2′FL and
LNnT became more similar to the microbiota profile of breastfed infants [42]. In our
study, we did not see any effect of the 2′FL/LNnT supplementation on α-diversity or
numbers of OTUs, as reflected by the unaltered Shannon index. However, 2′FL/LNnT
supplementation modulated the fecal, but not mucosal, microbial β-diversity profile of
patients in the group receiving the highest dose. The changes in the β-, but not in the
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α-diversity, might be related to the differences between these diversity metrics. The α-
diversity evaluates the microbiota community described by the number of OTUs and
relative abundance of individual samples [43]. Thus, the absence of α-diversity changes
throughout the intervention suggests an equilibrium between the numbers of species
present in the samples along with the intervention. In contrast, the β-diversity primarily
captures changes in community composition [43] and a higher dissimilarity due to the
intervention may reflect the niche competition and modulation of certain bacteria described
below. The fact that 2′FL/LNnT supplementation influenced the fecal but not mucosal
microbiota may be explained by the distinct microbiota profiles within the sampling
locations [5], or by the fact that 2′FL/LNnT is mainly consumed by the luminal microbiota,
potentially limiting the availability for mucosa-associated microbiota [44].
HMOs are directly consumed by certain Bifidobacterium spp. and Bacteroides spp. or
utilized by other bacterial taxa by cross-feeding [45,46], inducing microbial modulation.
In parallel, these changes may influence the abundance of other species due to niche
competition [47]. In our study, we found changes in the relative abundance of the four
most abundant OTUs Faecalibacterium, Lachnospiraceae and Blautia (Clostridiales order),
previously described to be altered in IBS patients relative to healthy individuals [48,49].
Of these, an increase of Faecalibacterium after 2′FL/LNnT intervention, often found in
low abundance in IBS, could be favorable in IBS management, whereas the benefit of
detected changes of Lachnospiraceae and the genus Blautia to may be debated as there is
still a lack of consensus in the so far few studies addressing the matter [48,49]. Several
studies have also described increased abundance of Bacteroides (i.e., Bacteroides fragilis) in
IBS compared to healthy controls (reviewed in [49]), a bacterial group considered to be
efficient consumers of HMOs, at least in infants [45,46]. The ability of Bacteroides fragilis to
degrade glycoproteins has been suggested to negatively influence the intestinal microenvi-
ronment, mucus production and intestinal motility, possibly triggering abdominal pain
and diarrhea [49]. In our study, the relative abundance of the genus Bacteroides was reduced
after 2′FL/LNnT intervention. Furthermore, Bifidobacterium spp., reported in lower levels
in IBS patients [49], was increased following the 2′FL/LNnT supplementation, similar to
previous reports in adults [29,32] and infants [42]. While the current study showed that
both 5 g and 10 g doses induced growth of bifidobacteria, our previous work demonstrated
similar effect only by the higher dose [32], a difference possibly explained by the different
methods used for analyzing the microbiota (16S rDNA sequencing vs. GA-map analysis).
The change of Bifidobacterium/Bacteroides ratio could be interpreted as being beneficial for
IBS patients, and the mechanisms should be investigated in more detail in future studies.
Nonetheless, the presence of an exogenous source of glycans that could indirectly prevent
degradation of host mucosal glycoproteins, and the competition between 2′FL/LNnT
consuming species [32] might be factors underlying such modulation. Additionally, vari-
ous strains of bifidobacteria have different capacities to metabolize HMO [27,45,46]. For
example, B. longum as well as B. adolescentis are known to utilize HMOs [27,50] and the
latter has been identified as the main responder to 2′FL/LNnT supplementation [29]. Our
intervention leading to an increased relative abundance of B. adolescentis in fecal samples
and B. longum and B. adolescentis in mucosal biopsies supports these mechanistic data.
Altogether, 2′FL/LNnT appears to contribute, directly or indirectly, to the modulation of
specific bacterial taxa that may be involved in the pathophysiology of IBS and, therefore, of
potential clinical benefit to this group of patients.
Metabolites reflect the function of the gut microbial community and influence host
health [16]. Together with the microbiota sequencing, the metabolite profiling contribute to
the understanding of the mechanisms of action of prebiotics [51]. For example, a dietary
intervention based on a yogurt with symbiotic properties led to altered concentrations of
serum metabolites such as acetone, choline, leucine and homocysteine, increased cell counts
of fecal Lactobacillus and improved GI health in IBS-D patients [52]. The knowledge of the
overall effects of HMO on the metabolite profile is currently scarce. Supplementation with
2′FL was demonstrated to change cecal microbiota and metabolite profiles and modulated
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gut-brain signaling in mice on a high-fat diet [53], and influenced cecal short-chain fatty
acids and the urine metabolite profile in a rat model [21]. Moreover, fermentation of
2′FL, LNnT and 2′FL/LNnT shifted concentrations of short-chain fatty acids in a human
sample based in vitro model system [22]. In our study, supplementation with 2′FL/LNnT
modulated the metabolite profiles of fecal and plasma samples. While 5 g 2′FL/LNnT
seemingly had a greater effect than 10 g dose on plasma samples, this was most likely due
to the relatively small group sizes. The lack of effect in urine samples may be attributed
to the fact that only half of the study subjects were included in this analysis, a limitation
of this study. In addition, the distinct metabolite compositions of feces, plasma and urine,
reflecting their diverse physiological functions, may explain that different 2′FL/LNnT doses
have different impact on the metabolite profile modulation. Furthermore, the modulation
of metabolite profiles differed between patients with and without an effect on bifidobacteria
abundance. Interestingly, the distinct metabolite profile modulation was characterized by
the change in fecal and plasma samples of asparagine, a metabolite thought to be important
for maintaining intestinal barrier function [54], and tryptophan, an essential amino acid
implicated in the pathogenesis of IBS [55]. One study showed that supplementation with B.
infantis in rats increased tryptophan abundance in plasma, suggesting normalization of the
tryptophan metabolism [55]. However, it needs to be acknowledged that the diet can also
influence the metabolite profile and our study did not specifically control for dietary habits,
except for advice to maintain the habitual diet throughout the study. The impact of the diet
may complicate the interpretation of the metabolite modulation linked to a distinct effect
on bifidobacteria abundance. Therefore, further investigation is needed to decipher the
causality between the bifidogenic effect seen in this work following HMO supplementation
and metabolite modulation.
Comparing breastfed infants with infants receiving formula demonstrated low but
detectable levels of HMOs in plasma and urine [20], and under certain conditions also
in feces [18]. In our study, 2′FL was detected in plasma and urine, but not in feces. The
leakage of 2′FL into the circulation has been suggested to have systemic effects, and lead to
lower plasma levels of inflammatory cytokines in breastfed infants and infants fed with
formulas containing 2′FL [24]. Additionally, while the overall plasma and urine levels of
2′FL increased in both groups receiving 2′FL/LNnT, some patients had low amounts of
2′FL at week 4. The flexible time window, 0–3 days, between the last supplement intake
and the collection of biological samples could explain the variation between patients within
the same treatment group. Of note, identification of 2′FL in plasma and urine in patients
supplemented with HMOs but not placebo, confirmed the study subjects’ adherence to
the study protocol. In contrast, LNnT was absent in the three sample types. Despite being
administered in a 4:1 ratio, the absence of LNnT in all samples, and the absence of 2′-FL
in fecal samples, suggests that the compounds were utilized by gut microbiota such as
for example Bifidobacterium spp. [18], which was found to increase in relative abundance
during the intervention, when reaching the large intestine.
Previous reports support that in healthy individuals, HMOs regulate tight junction
proteins [22], reduce permeability [22,23] and improve intestinal epithelial barrier func-
tion in vitro [22,23]. Furthermore, components of the host immune system such as pro-
inflammatory cytokines [22,24] can be regulated by HMOs and associated with gut health.
However, the effect of HMOs on the immune response in patients with IBS still needs
to be explored. Our study did not identify changes in the host mucosal response, eval-
uated by the expression of genes related to antibacterial response and intestinal barrier
integrity before and after 2′FL/LNnT intervention. A longer intervention period along
with non-targeted RNA sequencing analysis may be required to detect effects on host
mucosal response induced by 2′FL/LNnT supplementation.
This exploratory study provides proof-of-principle that 2′FL/LNnT supplementation
imprints several layers of data and ecosystems, represented by the different sample types
(i.e., feces, mucosal biopsies, plasma and urine). Compared to the GA-map analysis
used in our previous study targeting 54 bacterial taxa related to GI disorders [32], the
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use of 16S rDNA sequencing provided new insights into the effect of HMOs in the gut
microbiota composition of IBS patients. However, our study does not consider the potential
interactions between the different players in the intestinal microenvironment, which might
have provided an even better understanding of the effects of 2′FL/LNnT in host–metabolite–
microbiota crosstalk in IBS. Therefore, a study integrating multiple layers of data, as
previously suggested [17], will potentially offer an even more precise insight into the
mechanisms behind 2′FL/LNnT supplementation. Additionally, this study did not allow
us to relate the changes seen in microbiota or metabolite profiles to the improvement of the
patients, since the original clinical trial evaluated safety and was not aimed at assessing the
improvement of IBS symptoms. Nevertheless, the intestinal microenvironment modulation
described in this study, together with the improvement of IBS symptoms previously
reported in an open label trial with 2′FL/LNnT [31], indicate that 2′FL/LNnT promote gut
health by targeting bifidobacteria, and calls for further investigations in a larger cohort.
In summary, we showed that a 4-week supplementation with 2′FL/LNnT shaped the
gut microbiota in IBS patients, and specifically increased fecal and mucosal B. adolescen-
tis and mucosal B. longum. Additionally, supplementation with 2′FL/LNnT modulated
the fecal and plasma metabolite profiles, but did not influence host mucosal responses
throughout the intervention period. Furthermore, a distinct metabolite modulation was
linked to the bifidogenic effect throughout the intervention. Overall, our findings suggest
that 2′FL/LNnT supplementation might be a valuable strategy to improve the intestinal
microenvironment in IBS patients, although further studies are needed to decipher the
underpinning mechanisms and evaluate possible beneficial effects on IBS symptoms.
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